MYOD1 and myotonic dystrophy type 1: Noneof the compounds, including A2, reduced MyoD abundance as measured by RT-qPCR (Figure S23E), indicating that they do not induce dedifferentiation of DM1 myotubes.Notably, compounds B1 and B2, which exhibitno or weak RNA-binding affinity in vitro, rescuesplicing defects in DM1 patient-derived cells and produce measurableeffects in the NanoBRET assay, which may stem from an alternativemechanism rather than binding to the repeat expansion.